DiscoveryProbe™ FDA-approved Drug Library: High-Content Screening and Drug Repositioning Benchmarks

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) contains 2,320 bioactive compounds, each approved by at least one major regulatory body (FDA, EMA, HMA, CFDA, or PMDA) or listed in official pharmacopeias (ApexBio, 2024). The library encompasses diverse mechanisms, including receptor agonists/antagonists, enzyme inhibitors, and signal pathway modulators. It is formatted for high-throughput and high-content screening (HTS/HCS), supporting drug repositioning and new target identification in disease models (Li et al., 2024). Compounds are provided as 10 mM DMSO solutions, stable for 12–24 months at -20°C to -80°C, and are shipped under validated conditions. This resource enables reproducible, translational workflows in cancer, neurodegeneration, and signaling pathway research.

Biological Rationale

Mammalian or mechanistic target of rapamycin complex 1 (mTORC1) is a master regulator of cell growth, metabolism, and survival, integrating signals from growth factors and nutrients (Li et al., 2024). Dysregulation of mTORC1 signaling is linked to cancer, diabetes, aging, and neurodegenerative disorders. Targeting mTORC1 and related pathways with clinically approved compounds enables systematic interrogation of pharmacological mechanisms in disease-relevant contexts. The DiscoveryProbe™ FDA-approved Drug Library provides researchers with compounds targeting well-characterized pathways, such as kinase inhibition, receptor modulation, and epigenetic regulation, supporting the identification of new therapeutic strategies ( see discussion of translational breakthroughs; this article extends the mechanistic depth by mapping compounds to pathway targets validated in recent live-cell sensor studies).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

This compound library encompasses diverse mechanisms of action (MOAs). Key MOA categories include:

• Receptor Agonists and Antagonists: Compounds modulate GPCRs, nuclear hormone receptors, and receptor tyrosine kinases, affecting cell signaling and homeostasis.
• Enzyme Inhibitors: The library includes kinase inhibitors (e.g., AKT, mTOR), HDAC inhibitors (e.g., panobinostat), and protease inhibitors, which block enzymatic activity central to disease processes (Li et al., 2024).
• Ion Channel Modulators: Bioactive molecules modulate calcium, sodium, and potassium channels, relevant in neurodegenerative and cardiovascular models.
• Signal Pathway Regulators: Compounds influence pathways such as PI3K/AKT/mTOR, AMPK, and MAPK, enabling pathway-specific functional screens.

Representative compounds include doxorubicin (topoisomerase II inhibitor), metformin (AMPK activator), and atorvastatin (HMG-CoA reductase inhibitor), supporting broad pharmacological exploration. Recent studies demonstrate that HDAC inhibitors in the library can block nutrient-sensing to inhibit mTORC1 signaling, as visualized by live-cell biosensors (Li et al., 2024).

Evidence & Benchmarks

• The DiscoveryProbe™ FDA-approved Drug Library contains 2,320 unique, clinically validated compounds, each with traceable regulatory or pharmacopeial approval (ApexBio).
• Compounds are pre-dissolved at 10 mM in DMSO, ensuring standardized dosing and solubility for HTS/HCS platforms (ApexBio).
• HDAC inhibitors from the library, such as panobinostat, have been shown to inhibit mTORC1 activity via amino acid-sensing pathways in live-cell imaging assays (Li et al., 2024, DOI).
• mTORC1 pathway inhibition by library compounds is quantifiable using biosensors like TORSEL, supporting reproducible, image-based screening (Li et al., 2024, DOI).
• Library compounds are stable for 12 months at -20°C and 24 months at -80°C, with validated shipping on blue ice or at ambient temperature for secure delivery (ApexBio).
• Drug repositioning screens using this collection have accelerated target identification and translational research outcomes in oncology and neurodegeneration models (see workflow advances; this article clarifies how mechanistic screens benefit from live-cell biosensor endpoints).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library supports:

• High-throughput screening (HTS) for target validation and lead identification.
• High-content screening (HCS) with phenotypic and pathway-specific readouts.
• Drug repositioning studies leveraging compounds with established clinical safety profiles (see GPCR ligand discovery; this article extends evidence by linking MOA to live-cell mTORC1 inhibition).
• Mechanistic interrogation of disease models, including cancer, neurodegeneration, and metabolic disorders.
• Pharmacological modulation of signaling pathways, including PI3K/AKT, mTOR, and HDAC-mediated processes.

Common Pitfalls or Misconceptions

• Not all compounds are selective: Some drugs exhibit polypharmacology, complicating interpretation in pathway-specific screens.
• Approved status ≠ universal safety: Clinical approval does not guarantee suitability for all experimental models; context-specific toxicity must be considered.
• No coverage of experimental/proprietary compounds: The library includes only approved or pharmacopeial drugs, not investigational agents.
• Solubility in DMSO does not ensure aqueous stability: Some compounds may precipitate or degrade in water-based assay buffers.
• Phenotypic changes may reflect off-target effects: Validation of hit specificity is required, especially in complex cellular systems.

Workflow Integration & Parameters

The library is supplied as 10 mM DMSO solutions in 96-well, deep well, or 2D-barcoded screw-cap formats. Compounds are aliquoted for single-use or repeated screening, minimizing freeze-thaw cycles. Storage at -20°C (12 months stability) or -80°C (24 months stability) is recommended. Plates are compatible with automated liquid handling for HTS/HCS workflows. Shipping is performed on blue ice for evaluation samples; larger kits are shipped at ambient or on blue ice as required. Integration with live-cell biosensor readouts, such as the TORSEL mTORC1 sensor, enables real-time mechanistic profiling of compound effects (Li et al., 2024).

Researchers seeking robust, translational screening platforms may access the DiscoveryProbe™ FDA-approved Drug Library for validated, workflow-ready solutions. This article updates guidance provided in Applied Workflow Strategies by detailing recent advances in live-cell imaging–compatible HTS formats.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) is a rigorously curated foundation for high-throughput and high-content drug screening. Its clinical breadth, mechanistic diversity, and workflow compatibility empower translational research across cancer, neurodegeneration, and metabolic diseases. Recent integration of live-cell biosensors, such as TORSEL, enables direct visualization of pathway inhibition, as shown for mTORC1 and HDAC inhibitors (Li et al., 2024). As drug repositioning and pathway-driven screens become increasingly central to biomedical discovery, libraries like L1021 provide reproducible, scalable platforms for next-generation research.